Scarica l'app Stockscreener
1.96
2.49%
-0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Humacyte Inc Borsa (HUMA) Ultime notizie
Humacyte price target lowered to $8 from $10 at BTIG - Yahoo Finance
Humacyte’s Symvess Gains FDA Approval and Launches - TipRanks
Humacyte down following quarterly results, hits record low - Seeking Alpha
Durham biotech defends lead product after concerns surface - The Business Journals
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish - MSN
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive By Investing.com - Investing.com South Africa
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive - Investing.com India
Earnings call transcript: Humacyte Q4 2024 sees narrower EPS loss, stock edges up - Investing.com India
Humacyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Yahoo Finance
Humacyte CEO addresses concerns in NYT over FDA approval of Symvess - Investing.com
Humacyte responds to media coverage with SEC filing - Investing.com
Humacyte Defends Symvess Approval Amid FDA Scrutiny - TipRanks
Humacyte Earnings Preview - Benzinga
Durham biotech's stock price drops 30% amid offering, reports about product safety - The Business Journals
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
Humacyte Announces Public Offering to Raise $46.6 Million - TipRanks
Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel (NASDAQ:HUMA) - Seeking Alpha
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy? - MSN
Biggest stock movers Wednesday: GME, HUMA, DLTR, and more (HUMA:NASDAQ) - Seeking Alpha
FDA passes lab-grown blood vessel despite major concerns - Medical Brief
Humacyte stock slides on pricing public offering of units to raise $50M - MSN
Why Humacyte (HUMA) Stock Is Falling Sharply - Benzinga
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Humacyte stock plunges on public offering pricing By Investing.com - Investing.com South Africa
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 - TradingView
Major Biotech Innovation Updates Expected in Humacyte Q4 Earnings Call - StockTitan
Humacyte stock plunges on public offering pricing - Investing.com
Dollar Tree, GameStop, Humacyte - TradingView
Humacyte tumbles on pricing $50 mln stock offering - TradingView
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - Benzinga
Humacyte Secures $50M Funding: Major Push for SYMVESS Commercialization - StockTitan
Humacyte sets $2 stock offering, aims for $50 million - Investing.com
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - The Manila Times
Humacyte Prices Public Offering Of 25 Million Shares At $2.00 Per Share - Marketscreener.com
Humacyte announces public stock offering for expansion By Investing.com - Investing.com South Africa
Humacyte Shares Plunge After Hours: Here's WhyHumacyte (NASDAQ:HUMA) - Benzinga
Humacyte announces public stock offering for expansion - Investing.com India
Humacyte down 13% amid reports that FDA approved device despite warnings - Seeking Alpha
Humacyte Announces Proposed Public Offering Of Common Stock - Marketscreener.com
Humacyte, Inc. Announces Proposed Public Offering of Common Stock - Yahoo Finance
Humacyte To Present Fourth Quarter And Full Year Financial Results And Provide Corporate Update On March 28, 2025 - Marketscreener.com
Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know - MSN
FDA Approved Artificial Blood Vessel Despite Warnings - The New York Times
Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) - Seeking Alpha
Class Action Filed Against Humacyte, Inc. (HUMA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Humacyte, Inc. of Class Action Lawsuit and Upcoming DeadlinesHUMA - ACCESS Newswire
Individual investors who hold 41% of Humacyte, Inc. (NASDAQ:HUMA) gained 11%, institutions profited as well - Simply Wall St
HUMACYTE Earnings Preview: Recent $HUMA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Why Humacyte Stock Is Trading 15% Higher Monday - MSN
HC Wainwright Reiterates Buy Rating for Humacyte (NASDAQ:HUMA) - Defense World
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):